Philips has issued a correction for Trilogy Evo Platform Ventilators, according to the U.S. Food and Drug Administration (FDA).

This story is part of your SHN+ subscription Trilogy Health Services will focus on improving occupancy and tackling staffing ...

Using non-pneumatic nebulizers with the ventilators can lead to under-delivery of therapy to patients, the company said.

Philips (NYSE:PHG) has issued corrections for some of its Trilogy Evo ventilator platforms due to multiple issues.